

Chemokines in the brain: beneficial or detrimental?

Carole Rovère




The role of inflammation

Inflammation is a cardinal host defense response to injury, tissue ischemia, autoimmune responses or infectious agents.

Locally, within tissues outside the brain, inflammation manifests by the classical features of swelling, redness, heat and often pain.

Invasion of circulating immune cells (lymphocytes and macrophages)
Induction or activation of inflammatory mediators such as cytokines, kinins, cyclooxygenase products..., which are produced locally.



Local and generalized inflammatory responses to limit proliferation pathogens:

- have clear benefits in infectious states when activated in a regular manner for a defined period of time.
- localize and eradicate the irritant and repair the surrounding tissue.
 - Production of acute phase proteins in the liver
 - Activation of the sympathetic nervous system
 - Changes in cardiovascular function
 - Altered neuroendocrine status


And behavioural changes which lead to energy conservation (fever...)

...which can limit bacterial proliferation


The inflammatory response: a deleterious process

- Excessive and inappropriate (in time, place and magnitude) inflammation increasingly implicated in diverse states including:
cancer, anorexia/cachexia, diabetes, obesity, atherosclerosis, heart diseases and CNS diseases.
- Acute and chronic inflammation is involved in energy balance deregulations.


The inflammatory response and cytokines/chemokines production



Cytokines/chemokines involved in acute and chronic inflammatory responses




The inflammation: a balance between pro- and anti- inflammatory cytokines




- **Old dogma:**
Brain as an “immune privileged ” organ which was not susceptible to inflammation or immune activation.
- **Actually:**
Does exhibit key features of inflammation:
 - Glial activation
 - Oedema
 - Systemic acute phase response with general inflammation
 - Complement activation
 - Synthesis of inflammatory mediators such as cytokines/chemokines
 - Invasion of immune cells

CNS inflammation contributes to many acute and chronic neurodegenerative disorders and energy balance deregulations.

Expression of inflammatory mediators in the CNS




Inflammation can influence the control of feeding behavior




Release of immune factors in the blood which can reach the brain and modulate the neuronal circuits controlling food intake and metabolism

The energy balance



Hypothalamic networks involved in regulation of feeding behavior



Hypothalamic inflammation and energy balance deregulations

Anorexia / weight loss



Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression

SOPHIE LAYÉ,¹ GILLES GHEUSI,¹ SANDRINE CREMONA,¹ CHANTAL COMBE,¹ KEITH KELLEY,² ROBERT DANTZER,¹ AND PATRICIA PARNET¹

Central Nervous System Mechanisms Contributing to the Cachexia–Anorexia Syndrome

Carlos R. Plata-Salamán, MD, DSc

From the Division of Molecular Biology, School of Life and Health Sciences, University of Delaware, Newark, Delaware, USA

Evidence that Lipopolysaccharide-Induced Anorexia Depends upon Central, Rather than Peripheral, Inflammatory Signals

Brent E. Wisse, Kayoko Ogimoto, Jingjing Tang, Marvin K. Harris, Jr., Elaine W. Raines, and Michael W. Schwartz

NF- κ B Activation in Hypothalamic Pro-opiomelanocortin Neurons Is Essential in Illness- and Leptin-induced Anorexia¹

Received for publication, September 29, 2009, and in revised form, January 15, 2010. Published, JBC Papers in Press, January 22, 2010. DOI: 10.1074/jbc.M109.070706

Pil-Geum Jang^{1,1}, Cheri Namkoong^{1,1}, Gil Myoung Kang¹, Man-Wook Hur², Seung-Whan Kim³, Geun Hyang Kim⁴, Yeoungsup Kang¹, Min-Jae Jeon¹, Eun Hee Kim¹, Myung-Shik Lee^{5,6}, Michael Karin^{1,7}, Ja-Hyun Baik^{8,9}, Joong-Yeol Park¹, Ki-Up Lee¹, Young-Bum Kim¹⁰, and Min-Seon Kim¹¹

Obesity



Consumption of a Fat-Rich Diet Activates a Proinflammatory Response and Induces Insulin Resistance in the Hypothalamus

Cláudio T. De Souza,* Eliana P. Araujo,* Silvana Bordin, Rika Ashimine, Ricardo L. Zollner, Antonio C. Boschero, Mário J. A. Saad, and Lício A. Velloso

Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet

Kelly A. Posey,¹ Deborah J. Clegg,² Richard L. Printz,¹ Jaeman Byun,³ Gregory J. Morton,⁴ Anuradha Vivekanandan-Giri,³ Subramaniam Pennathur,³ Denis G. Baskin,^{5,6} Jay W. Heinecke,⁷ Stephen C. Woods,⁸ Michael W. Schwartz,⁴ and Kevin D. Niswender^{9,1,10}

MyD88 Signaling in the CNS Is Required for Development of Fatty Acid-Induced Leptin Resistance and Diet-Induced Obesity


André Kleinridders,^{1,2,3,5} Dominik Schenten,^{4,5} A. Christine Köhner,^{1,2,3,5} Bengt F. Belgardt,^{1,2,3,5} Jan Mauer,^{1,2,3} Tomoo Okamura,^{1,2,3} F. Thomas Wunderlich,^{1,2,3} Ruslan Medzhitov,⁴ and Jens C. Brüning^{1,2,3,*}

Obesity is associated with hypothalamic injury in rodents and humans


Joshua P. Thaler,^{1,2} Chun-Xia Yi,³ Ellen A. Schur,² Stephan J. Guyenet,^{1,2} Bang H. Hwang,^{1,2,4} Marcelo O. Dietrich,⁵ Xiaolin Zhao,^{1,2,6} David A. Sarruf,^{1,2} Vitaly Izgur,⁷ Kenneth R. Maravilla,⁷ Hong T. Nguyen,^{1,2} Jonathan D. Fischer,^{1,2} Miles E. Matsen,^{1,2} Brent E. Wisse,^{1,2} Gregory J. Morton,^{1,2} Tamas L. Horvath,^{5,8} Denis G. Baskin,^{1,2,4} Matthias H. Tschoöp,⁹ and Michael W. Schwartz^{1,2}

Actors of inflammation

Cellular actors




Molecular actors




Actors of inflammation

Cellular actors




Molecular actors




Chemokines and their receptors

Chemokines: chemoattractant cytokines
Known for attracting immune cells to infection/inflammed site

Chemokines families



Chemokines receptors



Redundant system



Roles of chemokines in the brain

European Journal of Neuroscience, Vol. 21, pp. 701–710, 2005

© Federation of European Neuroscience Societies

Complex effects of stromal cell-derived factor-1 α on melanin-concentrating hormone neuron excitability

A. Guyon,¹ G. Banisadr,² C. Rovère,¹ A. Cervantes,¹ P. Kitabgi,² S. Melik-Parsadaniantz² and J.-L. Nahon¹

Are chemokines the third major system in the brain?

Martin W. Adler^{*,†,1} and Thomas J. Rogers^{*,†,‡}

^{*}Center for Substance Abuse Research, [‡]Fels Institute for Cancer Research and Molecular Biology, [†]Department of Pharmacology, Temple University School of Medicine, Philadelphia, Pennsylvania

The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4

Céline Callewaere^{**}, Ghazal Banisadr^{**}, Michel G. Desarménien⁵¹¹, Patricia Mechighel^{**}, Patrick Kitabgi^{**}, William H. Rostène^{***}, and Stéphane Mélik Parsadaniantz^{**}

Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation

Astrid E. Cardona,¹ Meizhang Li,¹ Liping Liu,¹ Carine Savarin,¹ and Richard M. Ransohoff²

Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

OPINION

Chemokines: a new class of neuromodulator?

William Rostène, Patrick Kitabgi and Stéphane Mélik Parsadaniantz

Some facts about chemokines in the CNS

- Regulation of leukocyte infiltration into the brain
- Immune-glia cell communication
- Physiological intracellular communications
- Neurotoxicity/Neuronal survival
- Brain development
- Constitutively expressed in the brain
- **Neuromodulation**
- etc


For each pathology, an inflammation state



High-grade inflammation with high levels of pro-inflammatory mediators

Acute, often limited in time

Inflammation by systemic infection, lesion, cancer ...



Low-grade inflammation with low levels of pro-inflammatory mediators

Chronic

Aseptic inflammation, metabolic inflammation


For each pathology, an inflammation state



High-grade inflammation with high levels of pro-inflammatory mediators

Acute, often limited in time

Inflammation by systemic infection, lesion, cancer ...




Low-grade inflammation with low levels of pro-inflammatory mediators

Chronic


Aseptic inflammation, metabolic inflammation

Weight loss and inflammation



Hypothesis

high-grade inflammation in the hypothalamus



Our model: LPS-induced inflammation

LPS stereotaxic central (icv) injection (3V)




or

LPS peripheral (ip) injection



LPS injection induces weight loss

icv LPS




LPS injection induces inflammation in the hypothalamus

icv LPS
500ng



icv LPS-induced fold up-regulation
vs control group in the hypothalamus

Interleukins and other cytokines




LPS injection induces inflammation in the hypothalamus

icv LPS
500ng



icv LPS-induced fold up-regulation
vs control group in the hypothalamus



CCL2 is primarily involved in brain inflammation after ip LPS injection
(Thompson et al., 2008; Cazareth et al., 2014)

Can CCL2 mediate inflammation-induced weight-loss?



Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation

Strategy:
block central CCR2 signalling
pharmacologically and by use of transgenic animals




**icv injection of INCB3344
(inhibitor of CCR2)**



CCR2 KO mice


Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation

INFLAMMATION-ASSOCIATED WEIGHT LOSS



Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation

INFLAMMATION-ASSOCIATED WEIGHT LOSS





Blocking central CCR2 signalling reduces LPS-induced weight loss in mice



Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation



FOOD INTAKE



Blocking central CCR2 signalling partially rescues the LPS-induced decrease in food intake

Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation



FAT OXIDATION



Blocking central CCR2 signalling partially rescues the LPS-induced increase in fat oxidation and energy stores consumption


Central CCR2 signalling is required for metabolic and behavioural changes associated with inflammation

ACTIVITY





Blocking central CCR2 signalling partially rescues the LPS-induced decrease in locomotor activity


icv injected LPS activates the expression of pro-inflammatory cytokines



icv injected LPS increases CCL2 expression



icv injected LPS decreases MCH levels through CCR2 signalling




LPS injection induces hypothalamic CCL2 overexpression, thus over activation of central CCR2 signalling, which in turn mediates decrease in MCH expression





icv injected CCL2 activates the expression of pro-inflammatory cytokines


icv CCL2
100ng



icv injected CCL2 increases its own expression


icv CCL2
100ng







Like LPS, CCL2 icv injection induces inflammation in the hypothalamus with CCL2 overexpression and a decrease in MCH expression. This decrease totally depends on CCR2 central signalling.

CCL2 can directly modulate the activity of MCH neurons




MCH neurons express CCR2

CCL2 can directly modulate the activity of MCH neurons



CCL2 hyperpolarizes MCH neurons


CCL2 prevents MCH secretion



CCL2 blunts the release of MCH elicited by KCl and INCB3344 rescues provoked MCH secretion



Inflammation-induced weight loss may be driven by MCHR1 signalling




Antagonizing MCHR1 induces weight loss.
Co-injection of LPS and H6408 does not induce further weight loss whereas co-injection of CCL2 and H6408 shows early additive weight-loss.
Importance of the MCHR1 pathway in early times in the inflammation-induced weight loss.

Conclusion


Systemic high-intensity inflammation induces behavioral changes (sickness behavior) and inflammation in the hypothalamus, major brain structure for the control of feeding behavior.

LPS-induced sickness behavior is associated with weight-loss.



**Chemokines can directly affect hypothalamic circuits regulating energy balance.
What about other energy balance deregulations?**


For each pathology, an inflammation state



High-grade inflammation intensity with high levels of pro-inflammatory mediators

Acute, often limited in time

Inflammation by systemic infection, lesion, cancer ...




Low-grade inflammation intensity with low levels of pro-inflammatory mediators


Chronic

Aseptic inflammation, metabolic inflammation

Obesity and inflammation




brain
→ hypothalamus




white
adipose tissue



pancreas



liver



skeletal
muscle



gastrointestinal
tract

+ insulin resistance
(with hyperinsulinemia)

+ leptin resistance
(with hyperleptinemia)

MyD88 Signaling in the CNS Is Required for Development of Fatty Acid-Induced Leptin Resistance and Diet-Induced Obesity

André Kleinridders,^{1,2,3,5} Dominik Schenten,^{4,5} A. Christine Könner,^{1,2,3,5} Bengt F. Belgardt,^{1,2,3,5} Jan Mauer,^{1,2,3} Tomoo Okamura,^{1,2,3} F. Thomas Wunderlich,^{1,2,3} Ruslan Medzhitov,⁴ and Jens C. Brüning^{1,2,3,*}

Cell Metabolism, October 2009

Does Hypothalamic Inflammation Cause Obesity?


Brent E. Wisse¹ and Michael W. Schwartz^{1,*}

Cell Metabolism, Previews, October 2009

... diminished hypothalamic inflammation and leptin resistance protects against obesity...

Hypothesis


low-grade inflammation in the hypothalamus



Development of a murine Diet-Induced Obesity model



4 week-old male
C57Bl/6J mice




- Metabolic parameters (weight, food and water intake, leptinemia, ...)
- Inflammatory profile in the hypothalamus and serum
- Expression of hypothalamic neuropeptides involved in food intake regulation

Effects of Soy / Corn HFD consumption on weight gain ?



Weight gain




● HFD-fed mice have a weight of 10% higher compared to control animals from 8 weeks of diet

Effects of Soy / Corn HFD consumption on leptinemia ?



Serum leptin concentration




● HFD-fed mice show significant hyperleptinemia from 8 weeks of diet

Effects of Soy / Corn HFD consumption on metabolic parameters ?



Weight gain



Serum leptin concentration






- HFD-fed mice have a weight of 10% higher compared to control animals from 8 weeks of diet
- HFD-fed mice show significant hyperleptinemia from 8 weeks of diet
- **The first signs of obesity are observed after 8 weeks of Soy/Corn High-Fat Diet**




Effects of Soy / Corn HFD consumption on inflammatory profile ?



HYPOTHALAMUS





SERUM




- HFD consumption induces both peripheral and hypothalamic inflammation
- **Hypothalamic inflammation occurs before the peripheral inflammation**

Effects of Soy / Corn HFD consumption on hypothalamic neuropeptides expression?




- HFD consumption induces an early and stable increase of the orexigenic peptide MCH expression
- **Does this overexpression of MCH contribute to the development of obesity?**
Does inflammation contribute to this overexpression of MCH?

Link between CCL5 and weight ?




Link between CCL5 and weight ?



Effects of CCL5 injections in mice?


- on the weight?
- on the hypothalamic neuropeptides expression?

Effects of CCL5 central injection on weight?




IP injection induces a weight gain in mice after 72h post-injection

Effects of CCL5 central injection on weight?




IP injection induces a weight gain in mice after 72h post-injection




ICV injection induces a weight gain in mice after 24h post-injection

Effects of CCL5 injections on hypothalamic MCH expression?


MCH - mRNA after CCL5 IP injection




MCH concentration in hypothalamus after CCL5 IP injection



MCH - mRNA after CCL5 ICV injection




MCH concentration in hypothalamus after CCL5 ICV injection




Effects of CCL5 central injection on hypothalamic MCH expression?

MCH - mRNA after CCL5 IP injection




MCH concentration in hypothalamus after CCL5 IP injection




MCH expression is increased by IP CCL5 injection

MCH - mRNA after CCL5 ICV injection




MCH concentration in hypothalamus after CCL5 ICV injection




Effects of CCL5 central injection on hypothalamic MCH expression?

MCH - mRNA after CCL5 IP injection




MCH concentration in hypothalamus after CCL5 IP injection




MCH expression is increased by IP CCL5 injection

MCH - mRNA after CCL5 ICV injection




MCH concentration in hypothalamus after CCL5 ICV injection




MCH expression is increased by ICV CCL5 injection

Effect of CCL5 on MCH neurons activity ?




CCL5 induces a depolarization in 88% of MCH neurons, via a presynaptic release of glutamate



CCL5 induces a release of glutamate by both hypothalamic gliosomes and synaptosomes

Conclusion


The hypothalamic inflammation seems to play a primary role in the initiation of diet-induced obesity



CCL5, a major central actor in the initiation of obesity ?

A new role for chemokines

Chemokines could be a new class of neurotransmitter, neuromodulator or neuropeptide/neurohormone in the mature brain



Acknowledgements

Team of Jean-Louis Nahon, IPMC

Ophélie Le Thuc
Céline Cansell
Katharina Stobbe

Nadège Devaux
Kévin-Sébastien Coquelin
Françoise Presse

Fabienne Massa - Stéphane Berthezène - Laureline Bunod

Institut de la Vision, UMR S 968
INSERM, UMR 7210 CNRS, UPMC, Paris

William Rostène
Stéphane Mélik-Parsadaniantz
Annabelle Réaux Le Goazigo

Team of Catherine Heurteaux, IPMC

Nicolas Blondeau
Miled Bourourou
Alice Guyon

Team of S. Luquet,
Unité de Biologie Fonctionnelle Adaptative,
CNRS UMR8521, UPD Paris

Raphaël Denis

Microscopy platform, IPMC

Julie Cazareth
Frédéric Brau

Financial supports



Animal facility, IPMC

Véronique Thieffin



IPMC, 660 route des Lucioles, Sophia-Antipolis
06560 Valbonne France
www.ipmc.cnrs.fr



Thanks



Team of Dr Nahon
Genomics & evolution in neuro-endocrinology (GENE)



IPMC, 660 route des Lucioles, Sophia-Antipolis
06560 Valbonne France
www.ipmc.cnrs.fr

